期刊文献+

在体微透析技术研究低相对分子质量肝素凝胶经皮给药大鼠体内药动学特征 被引量:1

Analysis of Pharmacokinetic Characteristics of Low Molecular Weight Heparin Gel after Transdermal Adminstration by in Vivo Microdialysis Technique Combined with Colorimetric Method
原文传递
导出
摘要 目的考察低相对分子质量肝素凝胶经皮给药后大鼠皮肤和血液中低分子量肝素含量,评价其透皮药动学特征。方法SD大鼠腹部脱毛后经皮给予低分子量肝素凝胶,应用微透析采样技术结合比色法测定大鼠皮肤中低分子量肝素浓度随时间变化的影响,通过剪尾取血和Coatest Heparin试剂盒测定大鼠血液中低分子量肝素浓度随时间变化的影响。结果低分子量肝素凝胶经皮给药后,大鼠皮肤药物浓度达峰时间(tmax)为270 min、皮下最大药物浓度(cmax)是(4.40±0.54)IU·m L-1、t1/2为(137.04±87.98)min、AUC0-t为(911.76±330.69)IU·m L-1·min-1、MRT0-t为(322.67±40.94)min;大鼠血液内药物浓度达峰时间(tmax)为540 min、血液内最大药物浓度(cmax)是(2.23±0.40)IU·m L-1、t1/2为(294.99±183.74)min、AUC0-t为(110.59±212.41)IU·m L-1·min、MRT0-t为(422.48±52.96)min。结论在体微透析技术结合比色法可用于低分子量肝素凝胶透皮吸收药动学特征,方法操作简便、灵敏度高、专属性强。低分子量肝素凝胶经皮给药后具有缓慢透皮、浓度稳定的特点。 OBJECTIVE To determine the concentrations of low molecular weight heparin (LMWH) in dermal and plasma of rats after administration of LMWH gel to evaluate its pharmacokinetic characteristics. METHODS The rats were treated with abdominal hair removal, followed by administrating LMWH gel. The concentrations of LMWH in the dermal of rats at different time points were measured by microdialysis technique combined with colorimetric method, and the concentrations of LMWH in the blood of rats at differ- ent time points were measured by cutting-tail method and Coatest Heparin Kit. RESULTS The LMWH tmax in dermis was 270 min, Cmax was (4. 40 ±0. 54) IU· mL-1, t1/2 was (137.04±87.98) min, AUC0-t, was (911.76 ±330. 69) IU· mL · min-1 , MRTo-t, was (322. 67±40. 94) min; the LMWH t in plasma was 540 min, Cmax was (2. 23±0. 40) IU · mL-1 , t1/2 was (294. 99 ± 183.74) min, AUCo-t, was (110. 59 ±212. 41) IU · mL · min, MRT0-t, was (422. 48 ±52. 96) min after LMWH gel was percutaneous adminis- trated. CONCLUSION In vivo microdialysis technique combined with colorimetric method can be used for the evaluation of pharma- cokinetic characteristics of LMWH gel. The method has the advantages of simple operation with high sensitivity and specificity. LMWH gel have the characteristics of slow transdermal penetration speed and stabilized concentration.
作者 李超 胡晋红
出处 《中国药学杂志》 CAS CSCD 北大核心 2015年第21期1899-1904,共6页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(81173130)
关键词 低分子量肝素凝胶 经皮给药 微透析 药代动力学 low molecular weight heparin gel percutaneous administration microdialysis pharmacokinetics
  • 相关文献

参考文献2

二级参考文献24

  • 1汪昱,郑起,闫钧,汤钊猷.低分子肝素对肝癌生长和转移抑制作用的研究[J].中华普通外科杂志,2004,19(12):758-760. 被引量:11
  • 2Bobek V, Kovarvk J. Antitumor and antimetastatic effect of warfarin and heparin[J]. Biomed Pharmacother, 2004, 58:213-219.
  • 3Abdel-Salam OM, Baiuomy AR, Ameen A, et al. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat [J]. Pharmacol Res, 2005,51: 59-67.
  • 4Arikan S, Adas G, Barut G, et al. An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing [J]. Am J Surg, 2005, 189: 155-160.
  • 5Deepa PR, Varalakshmi P. Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis [J]. Clin Chim Acta, 2004, 339: 105-115.
  • 6Sundaram M, Qi Y, Shriver Z, et al. Rational design of low-molecular weight heparins with improved in vivo activity[J]. PNAS, 2003, 100: 651-656.
  • 7Pross M, Lippert H, Nestler G, et al. Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study [J]. lnt J Colorectal Dis,2004, 19: 143-146.
  • 8Carmeliet P, Jain RK. Angiogenesis in cancer and other disease [J]. Nature, 2000, 407: 249.
  • 9Brown S,Reynolds N J. Atopic and non-atopic eczema[J]. BMJ,2006,332(7541):584-588.
  • 10De Benedetto A,Agnihothri R,McGirt L Y,et al. Atopic dermatitis:a disease caused by innate immune defects[J]. J Invest Dermatol,2009,129(1):14-30.

共引文献23

同被引文献49

  • 1祖强,狄留庆,赵晓莉,黄耀洲,于燕燕,毕肖林.穴贴定喘膏体外透皮试验用皮肤的比较研究[J].中草药,2007,38(4):519-521. 被引量:3
  • 2PONEC M. In vitro cultured human skin cells as alternatives to animals for skin irritancy screening [J]. Int J Cosmet Sci,1992,14(6):245-264.
  • 3VAN GELE M, GEUSENS B, BROCHEZ L, et al. Three dimensional skin models as tools for transdermal drug delivery: challenges and limitations[J]. Expert Opin Drug Deliv, 2011,8(6):705-720.
  • 4SCHMOOK F P, MEINGASSNER J G, BILLICH A. Comparison of human skin or epidermis models with human and animal skin in in vitro percutaneous absorption[J]. Int J Pharm, 2001,215(1-2):51-56.
  • 5OLIVEIRA G, BEEZER A E, HADGRAFT J, et al. Alcohol enhanced permeation in model membranes. Part I. Thermodynamic and kinetic analyses of membrane permeation[J]. Int J Pharm,2010,393(1-2):61-67.
  • 6DE JAGER M, GROENINK W, BIELSA I,et al. A novel in vitro percutaneous penetration model:evaluation of barrier properties with p-aminobenzoic acid and two of its derivatives[J]. Pharm Res,2006,23(5): 951-960.
  • 7SINK B, GARRIGUES T M, BALOGH G T,et al. Skin-PAMPA: a new method for fast prediction of skin penetration[J]. Eur J Pharm Sci,2012,45(5): 698-707.
  • 8ENGESLAND A, SKAR M, HANSEN T,et al. New applications of phospholipid vesicle-based permeation assay: permeation model mimicking skin barrier[J]. J Pharm Sci, 2013,102(5):1588-1600.
  • 9TROMMER H,NEUBERT R H. Overcoming the stratum corneum:the modulation of skin penetration[J]. Skin Pharmacol Physiol, 2006,19(2):106-121.
  • 10MENON G K, CLEARY G W, LANE M E. The structure and function of the stratum corneum[J]. Int J Pharm,2012,435(1):3-9.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部